Trial Profile
Significant Suppression of Angiogenetic Cytokines by Additional Short-Term Administration of Sorafenib in Transarterial Chemoembolization for Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 12 Feb 2013 New trial record